Clinical Report: Remembering Dr. Maria Iandolo New, Pioneer in Pediatric Endocrinology
Overview
Dr. Maria Iandolo New was a trailblazer in pediatric endocrinology, notably advancing the understanding and treatment of adrenal steroid disorders such as congenital adrenal hyperplasia (CAH). Her extensive research, clinical care, and leadership significantly shaped the field, mentoring generations of endocrinologists and pioneering genotype-phenotype correlations in CAH.
Background
Dr. New overcame early personal and academic challenges to become a leading physician-scientist in pediatric endocrinology. She founded the Division of Pediatric Endocrinology at Cornell Medical College and served as chair of Pediatrics during a time when few women held such positions. Her work focused on adrenal steroid disorders, including detailed phenotyping and genetic studies of CAH. She also held prominent leadership roles, including presidency of the Endocrine Society and editorship of The Journal of Clinical Endocrinology & Metabolism.
Data Highlights
Dr. New's research included a genotype-phenotype correlation study of over 1500 patients with 21-hydroxylase deficiency, the largest series described to date. She published more than 400 peer-reviewed articles and contributed to the identification of multiple novel steroid biosynthesis disorders. Her work led to the cloning and sequencing of CYP21A2 genotypes and the development of immunoassays for steroid hormones used in dynamic testing protocols.
Key Findings
Dr. New delineated congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency through detailed clinical and hormonal phenotyping.
She contributed to linking 21-hydroxylase deficiency to the HLA complex, facilitating genetic cloning and sequencing of CYP21A2 variants.
Her research expanded treatment approaches, including prenatal glucocorticoid therapy and noninvasive prenatal diagnosis using next-generation sequencing.
She helped identify novel human steroid biosynthesis disorders, such as apparent mineralocorticoid excess and glucocorticoid-remediable aldosteronism.
Dr. New was a dedicated clinician, providing meticulous bedside care for infants with salt-wasting crises and supporting families of children with rare endocrine diseases.
She fostered international collaborations to study rare adrenal disorders and mentored numerous leaders in pediatric endocrinology.
Clinical Implications
Dr. New's work underscores the importance of integrating detailed clinical phenotyping with genetic analysis to improve diagnosis and management of adrenal disorders like CAH. Her pioneering efforts in prenatal diagnosis and treatment highlight evolving strategies to mitigate disease impact early. Clinicians should consider multidisciplinary approaches and international collaboration when managing rare endocrine conditions, following her example.
Conclusion
Dr. Maria Iandolo New's legacy as a clinician, researcher, and mentor profoundly advanced pediatric endocrinology and adrenal disease understanding. Her contributions continue to influence clinical practice and research worldwide.
